Trial Profile
Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2011
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 05 Oct 2011 New trial record